Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GW856553 in COPD
NCT00642148Phase 2Completed
- Sponsor
- GSK
- Start
- Feb 2008
- Primary completion
- Jul 2009
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 2, randomised, double-blind trial of losmapimod in chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by GSK. Primary endpoint: Change from Baseline in percentage of neutrophils in induced sputum at 12 weeks. Started Feb 2008; status: completed.
02
Drugs
losmapimod
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT00642148.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00642148.